vs
Concrete Pumping Holdings, Inc.（BBCP）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Concrete Pumping Holdings, Inc.的1.8倍（$177.4M vs $98.9M），Concrete Pumping Holdings, Inc.净利率更高（5.4% vs 1.6%，领先3.7%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -3.2%），过去两年Concrete Pumping Holdings, Inc.的营收复合增速更高（4.8% vs -0.2%）
Concrete Pumping Holdings, Inc.是领先的混凝土泵送服务及相关设备租赁供应商，主要面向美国和英国市场，业务覆盖基础设施建设、商业地产开发、住宅建造等核心建筑领域，为各类项目提供高效安全的混凝土输送解决方案。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
BBCP vs PCRX — 直观对比
营收规模更大
PCRX
是对方的1.8倍
$98.9M
营收增速更快
PCRX
高出8.2%
-3.2%
净利率更高
BBCP
高出3.7%
1.6%
两年增速更快
BBCP
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $98.9M | $177.4M |
| 净利润 | $5.3M | $2.9M |
| 毛利率 | 43.8% | — |
| 营业利润率 | 17.0% | 3.9% |
| 净利率 | 5.4% | 1.6% |
| 营收同比 | -3.2% | 5.0% |
| 净利润同比 | -43.6% | — |
| 每股收益（稀释后） | $0.09 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BBCPPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $98.9M | $196.9M | ||
| Q3 25 | $94.2M | $179.5M | ||
| Q2 25 | $85.2M | $181.1M | ||
| Q1 25 | $78.0M | $168.9M | ||
| Q4 24 | $102.1M | $187.3M | ||
| Q3 24 | $100.6M | $168.6M | ||
| Q2 24 | $98.7M | $178.0M |
净利润BBCPPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $5.3M | — | ||
| Q3 25 | $3.7M | $5.4M | ||
| Q2 25 | $-4.0K | $-4.8M | ||
| Q1 25 | $-2.6M | $4.8M | ||
| Q4 24 | $9.4M | — | ||
| Q3 24 | $7.6M | $-143.5M | ||
| Q2 24 | $3.0M | $18.9M |
毛利率BBCPPCRX
| Q1 26 | — | — | ||
| Q4 25 | 43.8% | 79.5% | ||
| Q3 25 | 42.9% | 80.9% | ||
| Q2 25 | 42.5% | 77.4% | ||
| Q1 25 | 40.0% | 79.7% | ||
| Q4 24 | 45.3% | 78.7% | ||
| Q3 24 | 44.3% | 76.9% | ||
| Q2 24 | 42.3% | 75.1% |
营业利润率BBCPPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 17.0% | 1.2% | ||
| Q3 25 | 13.7% | 3.5% | ||
| Q2 25 | 9.7% | 4.7% | ||
| Q1 25 | 4.5% | 1.2% | ||
| Q4 24 | 18.8% | 13.2% | ||
| Q3 24 | 16.5% | -82.8% | ||
| Q2 24 | 12.2% | 15.9% |
净利率BBCPPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 5.4% | — | ||
| Q3 25 | 3.9% | 3.0% | ||
| Q2 25 | -0.0% | -2.7% | ||
| Q1 25 | -3.4% | 2.8% | ||
| Q4 24 | 9.2% | — | ||
| Q3 24 | 7.5% | -85.1% | ||
| Q2 24 | 3.1% | 10.6% |
每股收益（稀释后）BBCPPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.09 | $0.05 | ||
| Q3 25 | $0.07 | $0.12 | ||
| Q2 25 | $-0.01 | $-0.11 | ||
| Q1 25 | $-0.06 | $0.10 | ||
| Q4 24 | $0.16 | $0.38 | ||
| Q3 24 | $0.13 | $-3.11 | ||
| Q2 24 | $0.05 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $44.4M | $144.3M |
| 总债务越低越好 | $417.9M | — |
| 股东权益账面价值 | $264.8M | $653.9M |
| 总资产 | $879.5M | $1.2B |
| 负债/权益比越低杠杆越低 | 1.58× | — |
8季度趋势，按日历期对齐
现金及短期投资BBCPPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $44.4M | $238.4M | ||
| Q3 25 | $41.0M | $246.3M | ||
| Q2 25 | $37.8M | $445.9M | ||
| Q1 25 | $85.1M | $493.6M | ||
| Q4 24 | $43.0M | $484.6M | ||
| Q3 24 | $26.3M | $453.8M | ||
| Q2 24 | $18.0M | $404.2M |
总债务BBCPPCRX
| Q1 26 | — | — | ||
| Q4 25 | $417.9M | $372.2M | ||
| Q3 25 | $417.6M | $376.7M | ||
| Q2 25 | $417.3M | $580.5M | ||
| Q1 25 | $417.1M | $583.4M | ||
| Q4 24 | $373.3M | $585.3M | ||
| Q3 24 | $372.9M | — | ||
| Q2 24 | $372.6M | — |
股东权益BBCPPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $264.8M | $693.1M | ||
| Q3 25 | $261.3M | $727.2M | ||
| Q2 25 | $261.8M | $757.8M | ||
| Q1 25 | $260.7M | $798.5M | ||
| Q4 24 | $321.7M | $778.3M | ||
| Q3 24 | $314.7M | $749.6M | ||
| Q2 24 | $308.3M | $879.3M |
总资产BBCPPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $879.5M | $1.3B | ||
| Q3 25 | $886.0M | $1.3B | ||
| Q2 25 | $878.8M | $1.5B | ||
| Q1 25 | $912.9M | $1.6B | ||
| Q4 24 | $898.0M | $1.6B | ||
| Q3 24 | $890.8M | $1.5B | ||
| Q2 24 | $894.7M | $1.6B |
负债/权益比BBCPPCRX
| Q1 26 | — | — | ||
| Q4 25 | 1.58× | 0.54× | ||
| Q3 25 | 1.60× | 0.52× | ||
| Q2 25 | 1.59× | 0.77× | ||
| Q1 25 | 1.60× | 0.73× | ||
| Q4 24 | 1.16× | 0.75× | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | 1.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.5M | — |
| 自由现金流经营现金流 - 资本支出 | $1.9M | — |
| 自由现金流率自由现金流/营收 | 1.9% | — |
| 资本支出强度资本支出/营收 | 12.7% | — |
| 现金转化率经营现金流/净利润 | 2.72× | — |
| 过去12个月自由现金流最近4个季度 | $17.5M | — |
8季度趋势，按日历期对齐
经营现金流BBCPPCRX
| Q1 26 | — | — | ||
| Q4 25 | $14.5M | $43.7M | ||
| Q3 25 | $19.1M | $60.8M | ||
| Q2 25 | $24.7M | $12.0M | ||
| Q1 25 | $6.0M | $35.5M | ||
| Q4 24 | $22.4M | $33.1M | ||
| Q3 24 | $35.0M | $53.9M | ||
| Q2 24 | $9.1M | $53.2M |
自由现金流BBCPPCRX
| Q1 26 | — | — | ||
| Q4 25 | $1.9M | $43.5M | ||
| Q3 25 | $4.3M | $57.0M | ||
| Q2 25 | $11.1M | $9.3M | ||
| Q1 25 | $191.0K | $26.9M | ||
| Q4 24 | $16.1M | $31.0M | ||
| Q3 24 | $26.4M | $49.8M | ||
| Q2 24 | $-1.9M | $51.6M |
自由现金流率BBCPPCRX
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 22.1% | ||
| Q3 25 | 4.6% | 31.7% | ||
| Q2 25 | 13.0% | 5.1% | ||
| Q1 25 | 0.2% | 15.9% | ||
| Q4 24 | 15.8% | 16.6% | ||
| Q3 24 | 26.2% | 29.6% | ||
| Q2 24 | -1.9% | 29.0% |
资本支出强度BBCPPCRX
| Q1 26 | — | — | ||
| Q4 25 | 12.7% | 0.1% | ||
| Q3 25 | 15.7% | 2.2% | ||
| Q2 25 | 16.0% | 1.5% | ||
| Q1 25 | 7.5% | 5.1% | ||
| Q4 24 | 6.2% | 1.1% | ||
| Q3 24 | 8.6% | 2.4% | ||
| Q2 24 | 11.2% | 0.9% |
现金转化率BBCPPCRX
| Q1 26 | — | — | ||
| Q4 25 | 2.72× | — | ||
| Q3 25 | 5.16× | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 4.63× | — | ||
| Q2 24 | 3.00× | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BBCP
| US Concrete Pumping | $72.2M | 73% |
| US Concrete Waste Management Services | $21.3M | 22% |
| Other | $5.4M | 5% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
